Life (Aug 2023)

Role of Perilesional Sampling of Patients Undergoing Fusion Prostate Biopsies

  • Riccardo Lombardo,
  • Giorgia Tema,
  • Antonio Nacchia,
  • Elisa Mancini,
  • Sara Franco,
  • Filippo Zammitti,
  • Antonio Franco,
  • Hannes Cash,
  • Carmen Gravina,
  • Alessio Guidotti,
  • Giacomo Gallo,
  • Nicola Ghezzo,
  • Antonio Cicione,
  • Andrea Tubaro,
  • Riccardo Autorino,
  • Cosimo De Nunzio

DOI
https://doi.org/10.3390/life13081719
Journal volume & issue
Vol. 13, no. 8
p. 1719

Abstract

Read online

Recently, researchers have proposed perilesional sampling during prostate biopsies to avoid systematic biopsies of patients at risk of prostate cancer. The aim of our study is to evaluate the role of perilesional sampling to avoid systematic biopsies of patients undergoing fusion biopsies. A prospective cohort of patients undergoing transrectal MRI transrectal fusion biopsies were consecutively enrolled. All the patients underwent systematic biopsies (SB), targeted biopsies (TB) and perilesional biopsies within 10 mm from the lesion (PB). The detection rates of different strategies were determined. A total of 262 patients were enrolled. The median age of those enrolled was 70 years. The mean BMI was 27 kg/m2, and the mean and prostate volume was 52 mL. A PIRADS score ≥ 4 was recorded in 163/262 (40%) patients. Overall, the detection rates of cancer were 43.5% (114/262) and 35% (92/262) for csPCa. The use of the target + peri-target strategy resulted in a detection of 32.8% (86/262) of cancer cases and of 29% (76/262) of csPCa cases (Grade Group > 2). Using the target plus peri-target approach resulted in us missing 18/262 (7%) of the csPCa cases, avoiding the diagnosis of 8/262 (3%) of nsPCa cases. A biopsy strategy including lesional and perilesional sampling could avoid unnecessary prostate biopsies. However, the risk of missing significant cancers is present. Future studies should assess the cost–benefit relationship of different strategies.

Keywords